Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Celgene Counts On Apremilast To Expand Inflammatory Disease Pipeline

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Second-quarter results spotlight 187 percent increase year-over-year in Revlimid revenues.

You may also be interested in...



Celgene Collaborates With Array BioPharma On Cancer, Inflammation Targets

Deal does not include candidates already in Array’s pipeline, firm tells “The Pink Sheet” DAILY.

Celgene Collaborates With Array BioPharma On Cancer, Inflammation Targets

Deal does not include candidates already in Array’s pipeline, firm tells “The Pink Sheet” DAILY.

Celgene Reports Positive Psoriasis Results For Anti-Inflammatory Candidate

Firm will outline a clinical and regulatory strategy for CC-10004 by late July, Celgene tells “The Pink Sheet” DAILY.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS066384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By